The neuroprotective effects of GLP-1R agonists and their exact mechanisms have been studied in Alzheimer’s disease, Parkinson’s disease, vascular brain injury, epilepsy, and other neuropathological diseases (14, 17, 18). This evidence concerns the gene GLP1R and early-onset autosomal dominant Alzheimer disease.